We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Ex-Biopure CEO Settles Blood Substitute Case

Law360 (February 21, 2007, 12:00 AM EST) -- Biopure Corp.’s former chief executive has resolved allegations that the pharmaceutical company continued to paint a rosy picture of its blood substitute awaiting approval, despite receiving negative feedback from U.S. federal regulators over the product’s safety.

Former CEO Thomas Moore agreed to shell out a $120,000 civil fine to settle charges that the company misled the public about its efforts to win Food and Drug Administration approval for its main product, Hemopure, according to the U.S. Securities and Exchange Commission on Wednesday.

Moore resolved the matter...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.